Hepatic colorectal cancer metastases showing a distinctive pattern of pathological response after metronomic capecitabine and bevacizumab

Medical Oncology

Volumn 29, Issue 4, 2012, Pages 2838-2841

  Pietrantonio, Filippo ^a   Biondani, Pamela ^a   Pellegrinelli, Alessandro ^a   Marchianò, Alfonso ^a   Dotti, Katia Fiorella ^a   Buzzoni, Roberto ^a   Bartolomeo, Maria Di ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Bevacizumab; Colorectal cancer; Liver metastases; Metronomic chemotherapy; Pathological complete response

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CARCINOEMBRYONIC ANTIGEN;

ADULT; ARTICLE; CANCER GROWTH; CANCER REGRESSION; CASE REPORT; COLORECTAL CANCER; COMPUTER ASSISTED TOMOGRAPHY; HEMICOLECTOMY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LIVER METASTASIS; LIVER RESECTION; LYMPH NODE DISSECTION; MALE; METRONOMIC DRUG ADMINISTRATION; PRIORITY JOURNAL; TREATMENT RESPONSE;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLORECTAL NEOPLASMS; DEOXYCYTIDINE; FLUOROURACIL; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84867946099     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-011-0132-5     Document Type: Article

References (24)

1. Kerbel RS, Kamen BA. The anti-angiogenic basis of metronomic chemotherapy. Nat Rev Cancer. 2004;4:423-36.
2. Gasparini G. Metronomic scheduling: the future of chemotherapy? Lancet Oncol. 2001;2:733-40.
3. Pasquier E, Kavallaris M, André N. Metronomic chemotherapy: new rationale for new directions. Nat Rev Clin Oncol. 2010;7:455-65.
4. Di Bartolomeo M, Bajetta E, Buzzoni R, et al. Efficacy of three different bevacizumab-containing first-line regimens for metastatic colorectal cancer: a randomized phase II study by italian trials in medical oncology (ITMO) Group. Tumori. 2010;10(1):S4 (Abstr A1).
5. Hanahan D, Bergers G, Bergsland E. Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice. J Clin Invest. 2000;105:1045-7.
6. Pasquier E, André N, Braguer D. Targeting microtubules to inhibit angiogenesis and disrupt tumour vasculature: implications for cancer treatment. Curr Cancer Drug Targets. 2007;7:566-81.
7. Laquente B, Viñals F, Germà JR. Metronomic chemotherapy: an antiangiogenic scheduling. Clin Transl Oncol. 2007;9:93-8.
8. Bergers G, Hanahan D. Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer. 2008;8:592-603.
9. Jain RK, Duda DG, Willett CG, et al. Biomarkers of response and resistance to antiangiogenic therapy. Nat Rev Clin Oncol. 2009;6:327-38.
10. Ebos JM, Lee CR, Cruz-Munoz W, et al. Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell. 2009;15:232-9.
11. Pàez-Ribes M, Allen E, Hudock J, et al. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell. 2009;15:220-31.
12. Leonard G, Brenner B, Kemeny NE. Neoadjuvant chemotherapy before liver resection for patients with unresectable liver metastases from colorectal carcinoma. J Clin Oncol. 2005;23:2038-48.
13. Di Bartolomeo M, Van Cutsem E, Michael M, et al. Feasibility of metastasectomy in patients treated with first-line bevacizumab for MCRC: preliminary results from the first BEAT-study (first BEAT investigators). Ann Oncol. 2006;17(9) (Abstr 373P).
14. Ribero D, Wang H, Donadon M, et al. Bevacizumab improves pathologic response and protects against hepatic injury in patients treated with oxaliplatin-based chemotherapy for colorectal liver metastases. Cancer. 2007;110:2761-7.
15. Adam R, Wicherts DA, de Haas RJ, et al. Complete pathologic response after preoperative chemotherapy for colorectal liver metastases: myth or reality? J Clin Oncol. 2008;26:1635-41.
16. Mandard AM, Dalibard F, Mandard JC, et al. Pathologic assessment of tumor regression after preoperative chemoradioitherapy of esophageal carcinoma. Clinicopathologic correlations. Cancer. 1994;73:2680-6.
17. Losi L, Luppi G, Gavioli M, et al. Prognostic value of Dworak grade regression (GR) in patients with rectal cancer treated with preoperative radiochemotherapy. Int J Colorectal Dis. 2006;21:645-51.
18. Blazer DG III, Kishi Y, Maru DM, et al. Pathologic response to preoperative chemotherapy: a new outcome end point after resection of hepatic colorectal metastases. J Clin Oncol. 2008;25:5344-51.
19. Rubbia-Brandt L, Giostra E, Brezault C, et al. Importance of histological tumor response assessment in predicting the outcome in patients with colorectal liver metastases treated with neo-adjuvant chemotherapy followed by liver surgery. Ann Oncol. 2007;18:299-304.
20. Benoist S, Brouquet A, Penna C, et al. Complete response of colorectal liver metastases after chemotherapy: does it mean cure? J Clin Oncol. 2006;24:3939-45.
21. Poston G, Figueras J, Giuliante F, et al. Urgent need for a new staging system in advanced colorectal cancer. J Clin Oncol. 2008;26:4828-33.
22. Lubezky N, Metser U, Geva R, et al. The role and limitations of 18-fluoro-2-deoxy-d-glucose positron emission tomography (FDG-PET) scan and computerized tomography (CT) in restaging patients with hepatic colorectal metastases following neoadjuvant chemotherapy: comparison with operative and pathological findings. J Gastrointest Surg. 2007;11:472-8.
23. Chun YS, Vauthey JN, Boonsirikamchai P, et al. Association of computed tomography morphologic criteria with pathologic response and survival in patients treated with bevacizumab for colorectal liver metastasis. JAMA. 2009;302:2338-44.
24. Maru DM, Kopetz S, Boonsirikamchai P, et al. Tumor thickness at the tumor-normal interface: a novel pathologic indicator of chemotherapy response in hepatic colorectal metastases. Am J Surg Pathol. 2010;34:1287-94.